Haematologica (May 2019)
Replacing cyclophosphamide/cytarabine/mercaptopurine with cyclophosphamide/etoposide during consolidation/delayed intensification does not improve outcome for pediatric B-cell acute lymphoblastic leukemia: a report from the COG
- Michael J. Burke,
- Wanda L. Salzer,
- Meenakshi Devidas,
- Yunfeng Dai,
- Lia Gore,
- Joanne M. Hilden,
- Eric Larsen,
- Karen R. Rabin,
- Patrick A. Zweidler-McKay,
- Michael J. Borowitz,
- Brent Wood,
- Nyla A. Heerema,
- Andrew J. Carroll,
- Naomi Winick,
- William L. Carroll,
- Elizabeth A. Raetz,
- Mignon L. Loh,
- Stephen P. Hunger
Affiliations
- Michael J. Burke
- Department of Pediatrics, Children’s Hospital of Wisconsin, Milwaukee, WI
- Wanda L. Salzer
- U.S. Army Medical Research and Materiel Command, Fort Detrick, MD
- Meenakshi Devidas
- Department of Biostatistics, Colleges of Medicine and Public Health & Health Professions, University of Florida, Gainesville, FL
- Yunfeng Dai
- Department of Biostatistics, Colleges of Medicine and Public Health & Health Professions, University of Florida, Gainesville, FL
- Lia Gore
- Department of Pediatrics, Center for Cancer and Blood Disorders, Children’s Hospital Colorado and The University of Colorado School of Medicine, Aurora, CO
- Joanne M. Hilden
- Department of Pediatrics, Center for Cancer and Blood Disorders, Children’s Hospital Colorado and The University of Colorado School of Medicine, Aurora, CO
- Eric Larsen
- Department of Pediatrics, Maine Children’s Cancer Program, Scarborough, ME
- Karen R. Rabin
- Department of Pediatrics, Baylor College of Medicine, Houston, TX
- Patrick A. Zweidler-McKay
- ImmunoGen, Inc, Waltham, MA
- Michael J. Borowitz
- Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD
- Brent Wood
- Department of Laboratory Medicine, University of Washington, Seattle, WA
- Nyla A. Heerema
- Department of Pathology, The Ohio State University School of Medicine, Columbus, OH
- Andrew J. Carroll
- Department of Genetics, University of Alabama at Birmingham, AL
- Naomi Winick
- Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX
- William L. Carroll
- Department of Pediatrics, Perlmutter Cancer Center, New York University Langone Health, New York, NY
- Elizabeth A. Raetz
- Department of Pediatrics, Perlmutter Cancer Center, New York University Langone Health, New York, NY
- Mignon L. Loh
- Department of Pediatrics, Benioff Children’s Hospital and the Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, CA
- Stephen P. Hunger
- Department of Pediatrics, Children’s Hospital of Philadelphia and the Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
- DOI
- https://doi.org/10.3324/haematol.2018.204545
- Journal volume & issue
-
Vol. 104,
no. 5
Abstract
With modern chemotherapy, approximately 90% of patients with pediatric acute lymphoblastic leukemia are now cured. However, subsets of patients can be identified who remain at very high risk of relapse with expected 4-year disease-free survival rates
